SBUX: Strong Comps, an Unfinished Price RepairStarbucks CorporationBATS:SBUXSmalldikenergyStarbucks: Strong Comps Do Not Erase a Changed Revenue Perimeter Starbucks has a better comparable-sales reading and an unfinished daily price repair. My lean is neutral until a daily close above $106.25 is followed by a separate held retest. The stock remains above its 55-day EMA, but Friday closed beneath both an important Fibonacci retracement and the rising recovery guide. An earnings headline alone does not settle that conflict. This October 31 weekend review uses the completed October 30 daily bar and the company's October 29 fiscal fourth-quarter release. The options snapshot is last available weekend data, not a current intraday feed. There is no new Saturday stock session, trade or claimed fill. MACRO: HOUSEHOLD SPENDING MEETS FINANCING COSTS The Federal Reserve held its target range at 3.75%–4.00% on October 28. The October 29 advance GDP release put third-quarter real growth at a 3.4% annualized rate, compared with 2.2% in the second quarter. Those are aggregate conditions. They do not establish the purchasing behavior of a Starbucks customer or identify the cause of one stock's next-day move. For consumer discretionary businesses, I would connect that backdrop to transaction frequency, the average receipt, wages, occupancy and financing. An increase in the dollars on a receipt can coexist with a different change in customer visits. The next question is whether the revenue improvement can cover the costs needed to sustain it. That requires company evidence, not an inference from the GDP headline. FUNDAMENTAL: THE COMPARABLE STORE AND THE CONSOLIDATED GROUP DIFFER Starbucks reported global comparable sales up 7.2% in its fourth quarter ended September 27, 2026, with average ticket up 5.2% and comparable transactions up 1.8%. Consolidated revenue fell 4% to $9.1 billion, primarily because China retail operations converted to a licensed joint venture in the third quarter. The business perimeter changed, so these growth rates answer different questions. North American comparable sales increased 7.9%; international comparable sales increased 0.9%, with international comparable transactions down 2.8%. GAAP operating margin was 10.8%; non-GAAP operating margin was 14.0%. GAAP EPS was $0.59 and non-GAAP EPS $0.80. These are the company's quarterly measures, not a uniform result across regions or interchangeable accounting bases. Comparable sales ask how the qualifying store cohort performed under the company's definition. Consolidated revenue asks what the reporting group recognized. A change from operating stores directly to licensing can alter which sales and costs appear in the accounts. Comparing the growth rates without that bridge risks reading a structural accounting change as a simple contradiction in demand. The ticket and transaction percentages should also retain their labels. Multiplying rounded growth rates need not reproduce the rounded headline perfectly, and adding them is only an approximation. A higher receipt is not the same observation as a higher visit count. The international transaction decline deserves attention even while the global comparable-sales figure is positive. Margin then needs a separate explanation. Changes in restructuring expenses, revenue mix, operating costs and the licensed structure can all affect the denominator and profit contribution. I would reconcile comparable definitions, region results, adjustments and cash conversion before assuming a larger reported margin represents an identical improvement at every store. The release is evidence of reported results; sustained economics remains a question to test over subsequent periods. TECHNICAL: A RECOVERY CAN STALL BEFORE IT REVERSES The genuine native daily chart shows October 30 open $105.71, high $106.25, low $102.235 and close $103.67. The native 55-day EMA is about $99.57 and RSI about 63.41. Friday's close was below Thursday's $105.51 close. These observations support a recovery with a failed latest push, not a confirmed bull flag, triangle or Elliott count. The drawn Fibonacci anchors are the August 18 high $109.23 and October 8 low $87.35, a $21.88 range. Measured upward from the low, 50% is $98.29, 61.8% is $100.87184, 78.6% is $104.54768 and the 127.2% extension is $115.18136. The extension is a conditional reference, not a forecast. Chronological A–E labels identify actual swings rather than a claimed wave count. The recovery guide joins the October 8 low with the October 13 low of $90.52. Its October 30 projection is approximately $104.26. Friday closed below that guide and the $104.55 retracement while remaining above the EMA. That is why I want price repair to prove itself before preferring the upside route. Tanuki's selected November 6 cumulative profile identifies P1 at $101 and C1 at $107 as its put-side and call-side gamma walls. The two upside checkpoints are $109.23 and $115.18; the two downside checkpoints are $100.87 and $98.29. Those are six distinct decision levels. HVL $102 is additional model context and is not labeled a verified zero-gamma flip. The provider's profile reads Positive Gamma above its transition area while its selected net-gamma tile is negative. Those labels describe different displayed concepts; I do not turn the profile name into a claim that aggregate net gamma is positive. The saved data timestamp is October 31 at 15:00:06 Central. The native all-expiry export was captured at 19:35:53 Central and verified as SBUX across 14 expiries. Export time is not the underlying data time. An upside case needs a daily close above $106.25 and a later retest that holds. C1 $107 is the nearby obstacle before the $109.23 and $115.18 checkpoints. Losing $102.235 defeats that local repair attempt; a move below $90.52 damages the wider recovery structure. A downside case needs a daily close below $102.235 followed by a separate failed reclaim, exposing $100.87 and then $98.29. A held recovery above $106.25 defeats that local bearish case; accepted trade above $109.23 defeats its wider premise. Earnings gaps, a changed options profile, spreads and failed retests can invalidate a neat chart route. These levels are conditional research references, not execution instructions or guaranteed outcomes. Would you give more weight to the comparable-sales improvement, or require the changed revenue perimeter and a held $106.25 repair to agree before upgrading the outlook? The next scheduled macro data checkpoint is the November 25 second estimate of third-quarter GDP. It can revise the aggregate backdrop; it will not replace the next company-specific operating evidence.